DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Bioavailability Study of Isotretinoin Capsules 40 mg Under Fed Condition

Information source: Dr. Reddy's Laboratories Limited
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy

Intervention: Isotretinoin (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Dr. Reddy's Laboratories Limited

Official(s) and/or principal investigator(s):
Dr. Alpeshkumar Patel, MD, Principal Investigator, Affiliation: Lambda Therapeutic Research Limited


To characterise the pharmacokinetic profile of sponsor's test formulation Isotretinoin Capsules 40 mg in comparison to the reference formulation Amnesteem (Containing Isotretinoin) Capsules 40 mg after single oral dose administration to healthy, normal, adult, human male subjects under fed condition.

Clinical Details

Official title: Open Label, Balanced, Randomized, Two-treatment, Two-period, Two Sequence, Single Dose, Crossover, Oral Bioequivalence Study of Isotretinoin Capsules 40 mg of Dr. Reddy's Laboratories Limited, India Comparing With Amnesteem Capsules 40 mg of Mylan Pharmaceuticals Inc., in Healthy, Adult, Male Human Subjects Under Fed Conditions.

Study design: Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Area under curve (AUC)

Detailed description: An open label, balanced, randomized, two-treatment, two-period, two sequence, single dose, crossover, oral bioequivalence study of Isotretinoin Capsules 40 mg under fed conditions.


Minimum age: 18 Years. Maximum age: 45 Years. Gender(s): Male.


Inclusion Criteria:

- Healthy adult human male volunteers between 18 to 45 years of age (both inclusive)

living in and around Ahmedabad city or western part of India.

- Having a Body Mass Index (BMI) between 18. 5-27. 5 (both inclusive), calculated as

weight in kg / height in meter2.

- Not having any significant disease in medical history or clinically significant

abnormal findings during screening, medical history, physical examination,laboratory evaluations, 12- lead ECG and X-ray chest recordings.

- Able to understand and comply with the study procedures, in the opinion of the

principal investigator.

- Able to comply to use 2 forms of effective contraception methods simultaneously

during Isotretinoin study, and for 1 month after study.

- Able to give voluntary written informed consent for participation in the trial.

- Able to read and/or understand drug medication Guide either in English or in a

provided translation when given along with informed consent form. Exclusion Criteria

- Known hypersensitivity or idiosyncratic reaction to Isotretinoin or any of the

excipients including parabens or any related drug.

- History or presence of any disease or condition which might compromise the

haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal or any other body system.

- Ingestion of any medicine including herbal medicines at any time within 14 days

before dosing in Period I. In any such case subject selection will be at the discretion of the Principal Investigator.

- Any history or presence of asthma (including aspirin induced asthma) or nasal polyp

or NSAID induced urticaria.

- Use of any recreational drugs or history of drug addiction or testing positive in

prestudy drug scans.

- A recent history of harmful use of alcohol(less than 2 years), i. e. alcohol

consumption of more than 14 standard drinks per week (A standard drink is defined as 360 ml of beer or 150 ml of wine or 45 ml of 40% distilled spirits, such as rum,whisky, brandy etc) or consumption of alcohol or alcoholic products within 48 hours prior to receiving study medicine.

- Smokers, who smoke 10 or more than 10 cigarettes / day or inability to abstain from

smoking during the study.

- The presence of clinically significant abnormal laboratory values during screening.

- History or presence of psychiatric disorders.

- A history of difficulty in donating blood.

- Donation of blood (1 unit or 350 mL) or receipt of an investigational medicinal

product or participation in a drug research study within a period of 90 days prior to the first dose of study medication. Elimination half-life of the study drug should be taken into consideration for inclusion of the subject in the study.

Locations and Contacts

Lambda Therapeutic Research Ltd.,, Ahmedabad, Gujarat 380 061, India
Additional Information

Starting date: June 2011
Last updated: June 25, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017